Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in Primary Sjögren's Syndrome
NCT02495129Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ianalumab in primary Sjögren's syndrome, sponsored by Novartis. Planned start Dec 2015; status: withdrawn.
02
Drugs
ianalumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02495129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495129.